Dziki temu osoby stosujce analogi GLP-1 odczuwaj mniejszy gd i szybciej czuj syto po posikach
These recommendations are based on results that showed that GLP-1RA compared with insulin therapy (basal, premixed, or intensified basal-bolus regimens) have similar or even better efficacy in HbA1c reduction and a lower hypoglycemia risk, promotes weight loss instead of weight gain, and reduces the burden of drug administration frequency and self-monitoring of blood glucose [1, 2]
GLP-1 peptides like semaglutide and tirzepatide have produced 15 to 22 percent body weight loss in clinical trials
As these innovations progress through clinical development and regulatory approval, they are likely to increase patient adherence, broaden treatment eligibility, and create new commercial opportunities across obesity, diabetes, and other metabolic disorders
New studies showing risk of harm to Ozempic patients: If you have taken Ozempic or another GLP-1 drug such as Wegovy, Rybelsus, Saxenda, Trulicity, or Mounjaro and developed serious side effects, you may be entitled to compensation
